- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05939128
Une étude prospective non interventionnelle sur la prévalence précoce du cancer du sein HER2 négatif à haut risque et des mutations BRCA1/2 en Russie (ERA)
Une étude multicentrique, à un seul bras, non interventionnelle, observationnelle et prospective pour évaluer la prévalence de BRCA1/2m, les approches de traitement et les résultats chez les patientes atteintes d'un cancer du sein précoce à haut risque HER2 négatif en Russie
(Neo)adjuvant treatment approaches and outcomes
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Arkhangelsk, Russie
- Research Site
-
Barnaul, Russie
- Research Site
-
Belgorod, Russie
- Research Site
-
Chelyabinsk, Russie
- Research Site
-
Grozny, Russie
- Research Site
-
Irkutsk, Russie
- Research Site
-
Khanty-Mansiysk, Russie
- Research Site
-
Krasnodar, Russie
- Research Site
-
Krasnoyarsk, Russie
- Research Site
-
Moscow, Russie
- Research Site
-
Nal'chik, Russie
- Research Site
-
Nyzhny Novgorod, Russie
- Research Site
-
Ryazan, Russie
- Research Site
-
Saint Petersburg, Russie
- Research Site
-
Severodvinsk, Russie
- Research Site
-
Sochi, Russie
- Research Site
-
Ufa, Russie
- Research Site
-
Vladivostok, Russie
- Research Site
-
Yaroslavl, Russie
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Study population will consist of early breast cancer HER2-negative patients with high risk of recurrence with available medical history, surgery or biopsy FFPE from primary tumor. It is estimated that approximately 750 patients will be enrolled in approximately 25 sites
La description
Inclusion Criteria:
-
Patients aged ≥ 18 years old
-. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
-
Early HER2-negative BC (stages 2 and 3)
-
Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
-
Unknown BRCAm status or negative BRCAm PCR test
-
Performed surgical treatment (not more than 7 months before inclusion)
-. High risk of recurrence according to one or more criteria:
- incomplete pathomorphological response (in case of neoadjuvant therapy)
- CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
- presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
- ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
- Any other high risk criterion according to investigators opinion
-
The presence of postoperative or biopsy FFPE
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 3 months
- Confirmation that the subject was already included in this study before
- Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer
Délai: 3 years
|
The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median |
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population
Délai: 3 years
|
Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics. |
3 years
|
|
To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Délai: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Délai: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine the prevalence of HRR mutations in HER2-negative breast cancer
Délai: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To determine invasive disease-free survival in the HRRm population (including BRCA1/2)
Délai: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To evaluate concordance between P53 expression and BRCAm
Délai: 3 years
|
Testing the archived tumour specimen and blood |
3 years
|
|
To assess the quality of life in patients with various types of adjuvant systemic therapy
Délai: 3 years
|
completed WHOQOL-BREF questionnaire will be assessed |
3 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- D133HR00030
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .